price jul usd
outlook strong reit buy
buy rate reflect increas confid revenu earn
acceler stori result organ sale growth adjust ep out-
pace estim support thesi
thing like
 organ sale growth adj ep beat organ sale growth
outpac estim consensu life scienc
diagnost segment drove out-performance segment
report organ sale growth adjust ep also exceed
expect compar dbe consensu
 rais organ sale growth adjust ep guid follow
strong perform manag anticip organ
sale growth compar guid put forth
decemb analyst investor day also rais low end
adjust ep guidanc rang expect
 broad-bas strength macro environ hold steadi
report healthi strength broad-bas across product
geographi even posit manag report steadi growth
across compani industri orient busi mid-
singl digit growth pall industri strength aerospac process
industri water qualiti hach industri msd quarter
manag also note order trend remain steadi across industri
 pharma biotech growth remain healthi includ small molecul
market pharma biotech market remain healthi pall life
scienc busi grew doubl digit led broad-bas product demand
 solid china trend face tough comp china busi grew
driven continu strength across busi segment
high-singl digit product identif grew mid-singl digit
except water qualiti compani face challeng prior
year compar manag anticip china growth deceler
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
mid- high-singl digit pace due difficult compar
china busi grew high-teen rate
thing cautiou
 adj ep guid consensu guid toward adjust
ep rang came consensu estim
forecast plu organ sale growth
guid came well estim also outpac
consensu
rais pt
rais pt reflect higher sale ebitda forecast higher
ev/ebitda multipl roll forward valuat framework price tar-
get reflect enterpris valu use project level debt cash
ttm ebitda ex option multipl premium
life scienc tool peer group median ev/ftm ebitda ex option price
target also contempl pro-forma financi ramif announc
acquisit ge biopharma busi ipo dental busi
period end expense/ incom expense/ incom incom ep share share sale omx cash flow oper cash cash
period end asset cash account receiv expens current current equip intang asset liabil note payabl current portion lt account expens current lt liabil stockhold juli
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
deutsch bank and/or affili expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or affili receiv non-invest bank relat compens compani
within past year
compani client deutsch bank secur inc within past year time receiv
import disclosur requir non-u regul
